Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLVOCCO: Fluvoxamine vs placebo for early COVID-19 in Japan
jRCT2031220558Phase 2Active, not recruiting
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Fluvoxamine with Placebo (2 arms). Primary endpoint: Primary: Clinical exacerbation rate. Started Jan 2023; status: active, not recruiting.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220558.